OncoZenge AB (OSTO:ONCOZ) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ONCOZ OncoZenge AB OSTO:ONCOZ
26 GF Score
Price kr7.49
! 2 Warning Signs
View Full Analysis

What is OncoZenge AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

OSTO:ONCOZ vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, OncoZenge AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoZenge AB Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's Short Interest distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's Short Interest falls into.


OSTO:ONCOZ
26GF Score
OncoZenge AB OSTO:ONCOZ
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoZenge AB Business Description

Address Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
26GF Score

Get the complete analysis for OSTO:ONCOZ

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr7.49
Price